Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cool.
GNBT-I added another 35K shares @ 1.2 for total of 60 K for Lt .
It might be a blockbuster.Please read the news.
http://www.in-pharmatechnologist.com/news/ng.asp?n=65365-generex-bentley-insulin-biotech-diabetes
Look at new patents Generex has :::::::
PAT. NO. Title
1 6,979,668 Full-Text Cleaning compound for and method of cleaning valves and actuators of metered dose dispensers containing pharmaceutical compositions
2 6,849,263 Full-Text Pharmaceutical compositions for buccal delivery of pain relief medications
3 6,451,286 Full-Text Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
4 6,436,367 Full-Text Aerosol formulations for buccal and pulmonary application
5 6,432,383 Full-Text Method for administering insulin
6 6,375,975 Full-Text Pharmaceutical compositions for buccal and pulmonary application
7 6,350,458 Full-Text Mixed micellar drug deliver system and method of preparation
8 6,350,432 Full-Text Pressurized container having an aerosolized pharmaceutical composition
9 6,315,984 Full-Text Pressurized container having an aerosolized pharmaceutical composition
10 6,312,665 Full-Text Aerosol formulations for buccal and pulmonary application
11 6,294,153 Full-Text Aerosol pharmaceutical formulation for pulmonary and nasal delivery
12 6,290,987 Full-Text Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
13 6,271,200 Full-Text Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
14 6,231,882 Full-Text Mixed micellar delivery system and method of preparation
15 6,221,378 Full-Text Mixed micellar delivery system and method of preparation
16 6,214,375 Full-Text Phospholipid formulations
17 6,193,997 Full-Text Proteinic drug delivery system using membrane mime
Nice ;-0...i'm concentrated on GNBT now HOD 1.24..in & out twice HEPH for .53 profit.
GNTA vol is exploding
GNBT HOD 1.20.It might take off now.
NWO-I sold Itek last week.I will wait for the dust to settle before making any move.
ABTG .219/.22
GNBT 1.19/1.2
I shorted 2 k shares @ 7.34
HEPH,-i think it will be a good short after the pop.The CBS news seg will not help it much.imo
GNBT -Maybe 999 lol,seriously that 's how you'
d measure the momo. I bot 25k shares @ 1.10 on friday.
mbient Progresses to Advanced Grid Management Phase in Westchester Pilot
Business Wire - January 30, 2006 09:00
BOSTON, Jan 30, 2006 (BUSINESS WIRE) -- Ambient Corporation (OTCBB: ABTG), a leader in Broadband over Power Lines (BPL) technology solutions, announced today, along with Consolidated Edison (NYSE: ED) and the New York State Energy Research and Development Authority (NYSERDA), that they have finalized and signed the contract, previously announced, to provide funding by NYSERDA for enhancing Ambient's BPL pilot in Westchester County, New York. This enhancement of the Westchester pilot is aligned with the recent announcement by The New York State Public Service Commission (NYS PSC) that it is seeking to establish the framework for potential use of BPL technology by regulated utilities.
This Advanced Grid Management Phase to be undertaken by Consolidated Edison and Ambient with the NYSERDA funding will include added benefits and enhanced monitoring capabilities provided by Ambient's BPL solution such as indications of general circuit health for improved asset management, information on power quality events on the distribution system, enhanced outage management and response. An example of this kind of indication is the ability to predict failure through noise analysis of grid equipment on a real-time basis.
"NYSERDA's involvement with this project is driven by the need to help increase the reliability and the efficient management of the utility's local distribution systems. We believe that the power line communications aspect of BPL can potentially help Consolidated Edison and other utilities to improve power quality, system reliability and customer service," stated Peter R. Smith, President of NYSERDA.
NYSERDA will be funding up to $200,000 of the project.
Hyman Schoenblum, Vice President of Corporate Planning for Consolidated Edison, stated, "Finding ways to better serve our customers has always been our number one priority. We look forward to continue evaluating how Ambient's BPL solutions can assist us to do this, and are pleased that we are advancing from the initial pilot phase to the Advanced Grid Management Phase; a critical juncture in this project."
Arotech's MDT Forms Joint Venture in India for Armored Vehicles
Monday January 30, 8:17 am ET
Teams with Armor Materials Supplier MKU and Vehicle Body Builder JN Group to Create Concord Safety Solutions Limited
NEW DELHI, India--(BUSINESS WIRE)--Jan. 30, 2006--Arotech Corporation (NasdaqNM:ARTX - News) announced today that its Armor Division has entered into a joint venture with two prominent Indian companies for the design and manufacture of armored vehicles in India. The joint venture - Concord Safety Solutions Limited - will offer armored vehicles to the Indian military and paramilitary organizations.
http://biz.yahoo.com/bw/060130/20060130005547.html?.v=1
24 Pain Neutralizer is 3rd Best Selling Topical Pain Reliever in Canada in 2005, Outselling Ben-Gay'TM', Tiger Balm'TM' And Icy Hot'TM'
Monday January 30, 8:00 am ET
TORONTO--(BUSINESS WIRE)--Jan. 30, 2006--Swiss Medica, Inc. (OTCBB:SWME - News) is pleased to announce that according to AC Nielson sales rankings for the 52-week period ending December 24, 2005, the 30ml spray bottle of O24 Pain Neutralizer was ranked the 3rd best selling product, out of 257 products, in the topical analgesic pain relief category in Canadian drugstores, based on dollar sales at the retail level. O24 Pain Neutralizer was nationally launched in Canadian drugstores in September 2004.
http://biz.yahoo.com/bw/060130/20060130005143.html?.v=1
GNBT is the play today.There were like over 1000 posts on the Yahoo messages board on sunday,lol.
http://www.in-pharmatechnologist.com/news/ng.asp?n=65365-generex-bentley-insulin-biotech-diabetes
GNBT_Breaking News on Pharmaceutical Technology
Previous page : New insulin therapies – big players beware of biotech...
Print
New insulin therapies – big players beware of biotech...
27/01/2006- The big pharma companies may have dreamed of launching the world’s first non-injectable insulin, but it has been Canadian biotech company Generex that shattered this dream, bypassing EU and US regulatory processes and launching its inhaled insulin in Ecuador last November. But do biotech companies prove a real threat?
The approval of Oral-lyn, an oral (buccal) insulin spray product, which is delivered into the mouth by the company's proprietary RapidMist system, was mainly based on the results of clinical trials in Ecuador involving only 250 Type 2 diabetics.
Oral-lyn is now available in Ecuador for Type 2 diabetics and the company hopes to soon have it approved there for Type 1 diabetes and is now conducting a six-month study in this patient population.
In addition, the firm is planning to roll Oral-lyn out in several other South American countries later this year, however, Oral-lyn’s success will ultimately depend on whether it is able to receive approval and break into the more lucrative international markets.
The large-scale Phase III clinical trials required by regulators in the US, Europe, and elsewhere have not yet begun and whether Generex's product can stand up to the much tougher international standards remains to be seen.
Generex does however provide a nice case study, of a biotech company going it alone and so far achieving some success.
When asked the important question as to why, if the company is confident of the quality of their product, they chose to launch their product in South America, Fabio Chianelli, business development, Generex, told www.In-PharmaTechnologist.com:
“Regulatory approval in South America is much more relaxed than in other parts of the world. We launched here first to generate revenue from sales of the product in Ecuador, in order to finance larger costly Phase III trials.”
“Other small biotechnology companies are usually partnered with large pharmaceutical companies and do not need to take this route. For us, money is sensitive,” he said.
Oral-Lyn also tests the water of the potential for non-injectable insulin, as the rate of uptake in Ecuador may provide a good indication of how popular the big pharma’s new products will be when they are eventually released onto the world market.
Meanwhile, nasal insulin sprays, where insulin particles are inhaled through the nose and are then absorbed by the nasal mucous membrane, is another area of budding development.
Scientists have known for years that the nasal route of administration of is highly efficient, but successful nasal insulin products have been difficult due to low delivery payload, poor reproducibility or mucosal irritation.
Drug development firm Bentley believes that its intranasal product has conquered these problems and is more bioavailable than both the pulmonary inhaled and buccal insulin products coming on to market.
“Initial studies have shown that our product has a bioabsorption of 20 per cent compared with only 6–8 per cent for pulmonary inhaled insulin – that is a 3–4 times greater bioabsorption,” according to James Murphy, Bentley's chairman and CEO.
The company also expects its product to be cheaper compared to other non-injectable insulins, as it requires less insulin delivery. Because of this it will also be a more compact product, measuring 2.5 inches compared to other inhaled products that measure about 8 inches, said Murphy.
Phase III trials will begin in early 2006 and Bentley recently signed a license agreement with Korea’s Dong Sung and India’s Biocon to develop and market the product in 85 countries throughout Asia, Africa, and the Middle East upon approval.
However, Dr Nancy Bohannon, who specialises in research in and treatment of diabetes in the US remains skeptical of nasal insulin sprays, due to the small area of absorption in the nose and the number of variables that could interfere with dosing such as mucous, colds and allergies.
Moving on, Coremed has recently unveiled a drug-delivery platform technology, IVE (in-vivo encapsulation) that improves absorption of certain proteins and macromolecules such as insulin within the gastrointestinal tract and may pave the way for the first insulin capsule. This is still in the early stages of development.
However, again, Dr Bohannon believes that insulin absorption within the gastrointestinal tract would be too unpredictable with an insulin capsule.
Finally, transdermal insulin technologies are also in the early development phase. Japan's KSL is working on a process that uses electrical currents like insulin, across the skin. This process may be able to move up to 70 per cent of an insulin dose into the bloodstream, but at this stage appears to be a relatively slow method of insulin delivery.
Although none of these products pose an immediate threat to pulmonary insulin, the biotech pipeline is clearly buzzing and may yet be the seeding ground of the next generation of insulin.
Copyright - Unless otherwise stated all contents of this web site are © 2000/2006 – Decision News Media SAS – All Rights Reserved. For permission to reproduce any contents of this web site, please email our Syndication department: contact our Syndication department. Full details for the use of materials on this site can be found in the Terms & Conditions.
http://www.in-pharmatechnologist.com/news/ng.asp?n=65365-generex-bentley-insulin-biotech-diabetes
KEEP an eye on GNBT on monday..FDA approved PFE inhaler insulin powder.
Reuters
Pfizer inhaled insulin wins US approval
Friday January 27, 3:52 pm ET
WASHINGTON (Reuters) - Pfizer Inc.'s (NYSE:PFE - News) inhaled insulin powder for diabetics won U.S. approval on Friday, U.S. regulators said.
http://biz.yahoo.com/rb/060127/pfizer_insulin.html?.v=2
Dang it ,i forgot about MOTG today it's up 40%.
I'm out HEPH @6.34.
GVIS-I'm nippling here and surprised with the sell off w/good news.
NP Bro, HEPH 6.19/6.21 now.
CBS will run a seg on Nuclear Radiation this sunday.
I'm in HEPH for 2K shares 5.85.
http://www.cbsnews.com/stories/1998/07/08/60minutes/main13502.shtml
I'm in GNBT 25K @ 1.10. It might run in anticipation of the FDA meeting feb 10.GLTA
Press Release Source: Generex Biotechnology
Generex Biotechnology Announces FDA Pre-IND Meeting Scheduled for the Avian Flu Vaccine
Monday January 23, 7:30 am ET
Antigen Express Subsidiary Preparing to File IND Application
TORONTO--(MARKET WIRE)--Jan 23, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, will meet with the U.S. Food and Drug Administration (FDA) on February 10, 2006 to discuss requirements for the filing of an Investigational New Drug (IND) application for the novel Antigen Express vaccine to protect against the H5N1 avian influenza and the commencement of human clinical trials.
Nice trade MT .
I'm out of ARSC @ .45.
ARSC .42/.46 .
CHNR is on fire
TY..
Check the following report.
Emerging Stock Report: Fuel Cells Powering Growth
Jan 26, 2006 (M2 PRESSWIRE via COMTEX) -- The total stationary fuel cell market was at $45.2 million in 2001 and is expected to reach $11 billion by 2007. Fuel cells are expected to be one of the main stationary power sources within the next ten years. Market factors of economics, energy dependence, and environmental concerns are driving the development of this industry. Growing demand for energy and the deployment of alternative energy saving and generation technology is creating a market for fuel cells.
The Emerging Stock Report is initiating coverage on American Security Resources Corporation (OTCBB: ARSC) up 29% today ARSC is a holding company actively seeking to acquire companies and technologies that will advance the development of alternative energies. ARSC, through its Hydra subsidiary, is developing high volume mass producible hydrogen fuel cells.
Their current product is in the final stages of development and will be called the HydraStax fuel cell. It is intended to be the first modular, mass producible, fuel cell. The Unit is housed in a computer-like housing or HVAC unit, which will support 10 individual fuel cells, each generating 1KW. The fuel cell is designed to be completely interchangeable and each module will be hot-swappable. Included in the package will be bi-directional, remote monitoring, command and control software and a comprehensive set of monitors which will be supervised by the software. The company projects that in volume production a 6KW system will sell in the $4500-$5000 range which will result in a Cost /KW of roughly $650. This cost is expected to come down into the $400/ KW range with mass production efficiencies.
The emerging need for stationary Fuel Cell technology for the industrial / commercial sector for standby and remote power, and for high-end residential users, is evident. The Freedonia Group projects that the Fuel Cell Opportunity is currently a $5 billion segment of a Trillion dollar industry for reliable power and distributed generation for the digital economy. The Hydra Fuel Cell is the "first" mass producible fuel cell system which can provide the efficiency to rival traditional generated power from public utilities. The cost of this unit is one third that of competitive fuel cell units. The BTU consumption to usable power efficiency of the Hydra unit is double that of conventional oil burning generators. This product has the unique capability to allow an owner to generate power during off-hours at a cost of around $0.06/KW/hr to $0.08/KW/hr and to sell it back to the grid for $0.12 to $0.16/KW/hr, while supplying the owner's normal power needs during the day. In effect this unit becomes a cash generator for the owner, selling electricity for up to a 100% gross profit.
The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.
Get a Complimentary Subscription at www.emergingstockreport.com Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.
Safe Harbor
All material herein was prepared by the Emerging Stock Report (ESR) www.emergingstockreport.com based upon information believed to be reliable The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.
ESR's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements.
CONTACT: e-mail: ian@emergingstockreport.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
Geron Announces Improved Production Method for Human Embryonic Stem Cell-Derived Islet Cells
Business Wire - January 27, 2006 07:30
MENLO PARK, Calif., Jan 27, 2006 (BUSINESS WIRE) -- Geron Corporation (Nasdaq:GERN) announced today the presentation of a new production protocol to differentiate islet cells from human embryonic stem cells (hESCs) for the treatment of diabetes. Presented at the Stem Cells & Regenerative Medicine Meeting in San Francisco by Dr. Anish Majumdar, Geron's Senior Director of Cell Therapy Research, the presentation described an improved method of deriving islet cells that secrete insulin and glucagon and express the appropriate set of genetic markers confirming them to be human islet cells. Moreover, the new production method generates islet-like clusters that contain proliferating precursors, which if isolated, could potentially enable the scalable production of hESC-derived islets.
Geron scientists and collaborators previously described animal studies using transplanted hESC-derived islet-like clusters made by an earlier, less efficient method that nevertheless i) significantly extended the life of diabetic animals and ii) produced both insulin and glucagon in vivo, generating detectable human insulin in the animal's bloodstream. Animal studies using islet cells made by the new method are currently in progress at the University of Alberta, Edmonton, Canada, Geron's academic collaborators for the program.
"Nearly 200 million people worldwide have diabetes," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "Moreover, the incidence appears to be on the rise. Using cadaver-derived islets to treat insulin-requiring diabetics, our collaborators established proof of principle of cell-based therapies for the treatment of diabetes. The drawbacks of the cadaver-based approach are limitations of supply and product variation from donor to donor. As we improve our production method for hESC-derived islet cells and demonstrate their utility in animal models of diabetes, we take an important step toward the clinic."
Geron is a biopharmaceutical company focused on developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases.
They went from Exclusive to non exclusive so it's not big of a deal.GVIS might pop today.
DJ Samsung Elec Ends Distributor Pact With GVI Securities
01/27/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
WASHINGTON (Dow Jones)--GVI Securities Solutions Inc. (GVIS) disclosed Friday that Samsung Electronics Co. terminated a distributor agreement between the parties.
The security systems provider said in a document filed with the Securities and Exchange Commission that Samsung indicated it will continue doing business with GVI under a revised contract, but on a non-exclusive basis.
GVI had been Samsung's exclusive distributor of video surveillance and security products to professional end users, installers and resellers.
Samsung informed the company that its current policy isn't to be a party to exclusive distribution arrangements, the filing said.
GVI said that Samsung was entitled to terminate the distributor agreement because it didn't purchase the minimum amounts required to be purchased during 2005.
The company said it believes that Samsung will continue to supply it with sufficient security products to meet its needs and the needs of the professional end users, installers and resellers that it services.
In addition, GVI said it doesn't expect demand from its customers to be materially affected by the termination of the exclusive contract with Samsung.
-By Chad Clinton, Dow Jones Newswires; 202-862-1349; chad.clinton@dowjones.com
(END) Dow Jones Newswires
ical files for $70 million stock shelf
Fri Jan 27, 2006 06:30 AM ET
WASHINGTON, Jan 27 (Reuters) - Vical Inc. (VICL.O: Quote, Profile, Research) on Friday filed with regulators to sell up to $70 million in common and preferred stock from time to time.
Vical, which develops biopharmaceutical products based on its patented DNA delivery technologies, said in a registration statement with the U.S. Securities and Exchange Commission that it would use the proceeds from the shelf offering for general corporate purposes, including clinical trials, research and development, manufacturing and acquisitions.
Under a shelf registration, a company may sell securities in one or more separate offerings, with the size, price and terms to be determined at the time of sale.
Press Release Source: Sniffex, Inc.
Sniffex, Inc. Announces Agent Agreement for Egypt, Morocco, Algeria, Libya, and Tunisia
Thursday January 26, 6:42 pm ET
IRVING, TX--(MARKET WIRE)--Jan 26, 2006 -- Sniffex, Inc. ("Sniffex") (Other OTC:SNFX.PK - News), producers of Sniffex, an explosive detection device, and other homeland related products, announced today the signing of an exclusive marketing agreement with Smart Distributors & Suppliers (Smart) for Egypt, Morocco, Algeria, Libya and Tunisia. Smart is a provider of security equipment and training to airports and cargo handlers. Smart distributes a variety of products to Egypt from the US and other countries and believes that their contacts and sales abilities will combine to create quick sales to government and polices forces in the countries they represent.
ADVERTISEMENT
Sniffex, Inc. stated that the primary focus of their marketing strategy is to identify and sign agents throughout the world to distribute their products. Their stated goal is to have at least 20 agents by the end of 2006 that would sell to at least 100 countries around the world.
"We see a tremendous market need for a product like Sniffex," stated Khaled Jozilan, Managing Director of Smart. "We already have a distribution channel all over the Middle East and North Africa that will be very useful in a quick startup in the sales of Sniffex. We have already established relationships and have sold products to the same clients we will target for Sniffex sales," he continued.
"Smart Distributors represents a major step forward in our attempt to have Sniffex represented in 100 countries by the end of 2006," stated Paul Johnson, President of Sniffex, Inc. "Mr. Jozilan has made it clear that Sniffex's existing products and those that we intend to sell through this same channel are all exciting opportunities to grow revenue in his company."
About Sniffex
Sniffex, Inc. is the holder of the license to sell Sniffex, an explosives detection device, in most areas of the world. Its plan is to acquire additional homeland security related products and companies to expand the offerings that can be sold through the marketing channel it is currently establishing. It sells its products though agents, distributors, and its own sales force. The Company was formed in November 2004 and began and sold its first products in August of 2005.
Safe Harbor Act Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend" "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements due to a wide range of factors which are set forth in our annual report on Form 10-KSB on file with the SEC.
Lebed' latest pump.
I just listened to the WallSt.net interview.
MOTG's CEO said that the company will do $20 million per year in
revenues just like it is right now.
If they close on the acquisitions they are considering, he believes the
company will reach $55 million in annualized revenues during 2006.
If they meet the criteria, which the CEO believes they will if they
complete the acquisitions, he intends to apply and become listed on a
national exchange.
He anticipates that the company will soon become profitable and achieve
positive and cash building earnings during 2006.
-----
My firm Lebed Biz, LLC, has been compensated by MOTG $15,000 cash for a
one-month MOTG investor relations contract. Never invest into a stock
we discuss unless you can afford to lose your entire investment. For our
full disclaimer goto: www.lebed.biz/disclaimer.htm
Jonathan Lebed
Lebed.biz
Staff
Hi Art,long time no see ...Are u still in EZTO? Congrats on your Steelers, they costed me $5 K with their perfect game,lol.I hope they 'll have another perfect game cuz i'm taking them -3 1/2 in the SB.
I think this is the first time the 6th seed is favored over the 1st seed in the SB.
I realized that but most R/S sold off big until the dust settled and that's how i will play w/the stock.It might keep running till .68 because of Cuban's rep. GL
ITEK there's R/S talk 10:1 in the 14C.I'll will sell my shares tomorrow.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4145624&Type=HTML
BODIES ... The Exhibition To Open April 22nd in Houston at the John P. McGovern Museum of Health & Medical Science
Tickets to Must-See Exhibition Go on Sale on January 27th at 10AM
HOUSTON, Jan. 26 /PRNewswire-FirstCall/ -- BODIES ... The Exhibition, the widely acclaimed and controversial blockbuster exhibition featuring real human bodies, will open at the John P. McGovern Museum of Health & Medical Science in Houston on Saturday, April 22nd -- as the first exhibition of the kind ever to come to Texas. Tickets for the highly anticipated exhibition will go on sale this Friday, January 27th at 10AM and can be obtained by logging onto www.BodiesTickets.com or by calling 877-77-CLICK (25425). Responding to widespread public interest and demand, this announcement was made today by Premier Exhibitions, Inc. (OTC Bulletin Board: PXHB), in association with Concert Productions International and Jam Exhibitions, and with the John P. McGovern Museum of Health & Medical Science. The exhibition will be open 7 days a week: Monday - Wednesday 9AM - 7PM; and Thursday - Sunday 9AM - 9PM.
Organizers anticipate high demand for the tickets to the eye-opening exhibition which reveals 'what lies beneath' our skin. Similar exhibitions have attracted nearly 20 million people worldwide. When BODIES ... The Exhibition opened in Tampa, Florida at the Museum of Science & Industry, ticket-buyers lines stretched out the door. Since opening in August in Tampa, BODIES ... The Exhibition has attracted more than 275,000 visitors of all ages -- including 30,000 students from elementary through high school classes, as well as young professionals, families, and seniors -- surpassing all of the Museum's attendance records and becoming the Museum's single most successful exhibition in its history. In light of this, organizers urge the public to purchase advance tickets to ensure admittance when the exhibition opens in April.
BODIES ... The Exhibition will be a 20,000-square-foot exhibition featuring more than 20 whole-body specimens and more than 250 organs and partial body specimens that will give visitors the opportunity to see their own bodies in a fascinating way they never have before. These meticulously dissected whole-body specimens are featured to show the visitors the complex systems involved in the activities that are a part of daily life. The exhibition will change the way people see themselves. It is designed to enlighten, empower, fascinate, and inspire.
Bringing this ground-breaking exhibition to Houston is the latest milestone in the highly successful campaign to grow and expand the John P. McGovern Museum of Health & Medical Science under the direction and vision of CEO Tadd Pullin. The Museum has attracted a 50 percent increase in new membership growth and overall attendance in 2005, and has aggressive plans for 2006. Since the Museum was founded in 1996, the Texas Medical Center and its constituency have supported its efforts to be a vehicle through which some of the world's finest health institutions can educate families on health, wellness, and the science of life. The Museum's Board of Directors is comprised of leading TMC executives and professionals as well as health system leaders.
The organizers of BODIES ... The Exhibition have similar exhibitions currently open in New York City at the South Street Seaport Exhibition Centre and at the Museum of Science & Industry in Tampa, Florida where they continue to draw record crowds. Premier Exhibitions, Inc. is a major provider of museum quality touring exhibitions throughout the world, including 'Titanic: The Artifact Exhibition,' and 'Bodies Revealed.' CPI is a multi-faceted entertainment entity with expertise in all areas of live concert and event production including tour marketing, merchandising, sponsorship, broadcast, home entertainment, as well as theatrical productions, including Broadway's smash hit 'Spamalot' and the new 'Lord of the Rings' stage production, and has promoted 5 of the 6 top grossing concert tours of all time including tours by the Rolling Stones, Pink Floyd, U2 and Crosby, Stills, Nash and Young. Jam Exhibitions is a division of Jam Productions, the largest independent promoter of live entertainment in the United States.
Premier Exhibitions, Inc. is not affiliated with any other organizer of human anatomy exhibitions, including Gunther von Hagens, Gerhard Perner, or Genlife Biomedical. BODIES ... The Exhibition should not be confused with 'Body Worlds,' 'Body Exploration,' 'The Universe Within,' 'Bodies Revealed,' or any other human anatomy exhibition.
Media Contacts: Holly Taylor Jennifer Evans
Rogers & Cowan John P. McGovern Museum of
212-445-8446 Health & Medical Science
hetaylor@rogersandcowan.com 713-942-7054 ext. 272
jevans@mhms.org
SOURCE Premier Exhibitions, Inc.
Source: PR Newswire (January 26, 2006 - 6:20 PM EST)
Cool.
ARSC float is only 5 MM shares.This baby can run hard tomorrow.
YEP,the News hasn't reached a lot of traders.Tomorrow will be fun.
ARSC Hydra Unit Demo's Hydrogen Fuel Cells to Government and Industry
Business Wire - January 26, 2006 15:22
HOUSTON, Jan 26, 2006 (BUSINESS WIRE) -- American Security Resources Corporation (OTCBB:ARSC) announced today that its Hydra Fuel Cell Corporation subsidiary successfully demonstrated beta units of its proprietary HydraStax(TM) hydrogen fuel cells in Beaverton, Oregon, on January 20, 2006.
Ed Davis, Chairman of Hydra, said, "We had over twenty representatives of industry and government here to see the working beta units. The units performed flawlessly and the response from the attendees was very enthusiastic. We are currently following up on the requests for additional data from some of the groups who participated in the demo. We are expecting some to order units."
The HydraStax(TM) is designed to be the first commercially mass producible hydrogen fuel cell. ARSC believes the market for this type of fixed power unit in military and commercial applications could number in the hundreds of thousands.
American Security Resources Corporation
ARSC is a holding company actively seeking to acquire companies and technologies that will advance the development of alternative energies. ARSC, through its Hydra subsidiary, is developing high volume, mass producible hydrogen fuel cells. For more information, please see: www.americansecurityresources.com
I'm in ARSC 25 K @ .28
ARSC Hydra Unit Demo's Hydrogen Fuel Cells to Government and Industry
Business Wire - January 26, 2006 15:22
HOUSTON, Jan 26, 2006 (BUSINESS WIRE) -- American Security Resources Corporation (OTCBB:ARSC) announced today that its Hydra Fuel Cell Corporation subsidiary successfully demonstrated beta units of its proprietary HydraStax(TM) hydrogen fuel cells in Beaverton, Oregon, on January 20, 2006.
Ed Davis, Chairman of Hydra, said, "We had over twenty representatives of industry and government here to see the working beta units. The units performed flawlessly and the response from the attendees was very enthusiastic. We are currently following up on the requests for additional data from some of the groups who participated in the demo. We are expecting some to order units."
The HydraStax(TM) is designed to be the first commercially mass producible hydrogen fuel cell. ARSC believes the market for this type of fixed power unit in military and commercial applications could number in the hundreds of thousands.
American Security Resources Corporation
ARSC is a holding company actively seeking to acquire companies and technologies that will advance the development of alternative energies. ARSC, through its Hydra subsidiary, is developing high volume, mass producible hydrogen fuel cells. For more information, please see: www.americansecurityresources.com